CN1183136C - 吲哚并喹唑啉酮 - Google Patents

吲哚并喹唑啉酮 Download PDF

Info

Publication number
CN1183136C
CN1183136C CNB018126995A CN01812699A CN1183136C CN 1183136 C CN1183136 C CN 1183136C CN B018126995 A CNB018126995 A CN B018126995A CN 01812699 A CN01812699 A CN 01812699A CN 1183136 C CN1183136 C CN 1183136C
Authority
CN
China
Prior art keywords
alkyl
compound
formula
cycloalkyl
free alkali
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018126995A
Other languages
English (en)
Chinese (zh)
Other versions
CN1441803A (zh
Inventor
K����Ĭ
K·齐默尔曼
R·波特曼
D·F·里格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1441803A publication Critical patent/CN1441803A/zh
Application granted granted Critical
Publication of CN1183136C publication Critical patent/CN1183136C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
CNB018126995A 2000-07-17 2001-07-16 吲哚并喹唑啉酮 Expired - Fee Related CN1183136C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0017508.3 2000-07-17
GBGB0017508.3A GB0017508D0 (en) 2000-07-17 2000-07-17 Antimicrobials

Publications (2)

Publication Number Publication Date
CN1441803A CN1441803A (zh) 2003-09-10
CN1183136C true CN1183136C (zh) 2005-01-05

Family

ID=9895801

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018126995A Expired - Fee Related CN1183136C (zh) 2000-07-17 2001-07-16 吲哚并喹唑啉酮

Country Status (18)

Country Link
US (1) US6964960B2 (enExample)
EP (1) EP1303517B1 (enExample)
JP (1) JP3939246B2 (enExample)
CN (1) CN1183136C (enExample)
AR (1) AR031379A1 (enExample)
AT (1) ATE262530T1 (enExample)
AU (1) AU2001279754A1 (enExample)
BR (1) BR0112521A (enExample)
CA (1) CA2415683C (enExample)
DE (1) DE60102473T2 (enExample)
DK (1) DK1303517T3 (enExample)
ES (1) ES2218439T3 (enExample)
GB (1) GB0017508D0 (enExample)
MY (1) MY133969A (enExample)
PE (1) PE20020210A1 (enExample)
PT (1) PT1303517E (enExample)
TR (1) TR200401026T4 (enExample)
WO (1) WO2002006284A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
AU2006219023A1 (en) 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Tetracyclic Amino and Carboxamido Compounds and methods of use thereof
BRPI0615096A2 (pt) 2005-08-24 2009-07-14 Inotek Pharmaceuticals Corp análogos de indenoisoquinolinona e métodos de uso dos mesmos
MX2008016339A (es) 2006-06-20 2009-01-16 Abbott Lab Pirazoloquinazolinonas en la forma de inhibidores parp.
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
MX2009009183A (es) 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
EP2157972A1 (en) 2007-05-08 2010-03-03 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
CN103703002B (zh) * 2011-07-13 2016-05-11 参天制药株式会社 具有parp抑制活性的新型化合物
CN102766144B (zh) * 2012-07-10 2014-04-23 浙江大学 一种吲哚并[1,2-c]喹唑啉化合物的制备方法
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN111819282A (zh) 2018-03-13 2020-10-23 欧恩科斯欧公司 对抗癌症治疗中获得性耐药性的Dbait分子
US20220073531A1 (en) * 2018-11-30 2022-03-10 Merck Patent Gmbh Compounds for electronic devices
US20220162205A1 (en) * 2019-03-12 2022-05-26 Merck Patent Gmbh Materials for organic electroluminescent devices
CN110357892B (zh) * 2019-07-10 2022-06-07 云南大学 四氢嘧啶并[1,2-a]吲哚衍生物及其合成方法与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114195789B (zh) * 2021-12-15 2022-09-09 广东海洋大学 一种无金属参与的多环吲哚衍生物的制备方法
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635966A (en) 1969-10-22 1972-01-18 Robins Co Inc A H 6-substituted-indolo(1 2-c)quinazolines
DE2237372C3 (de) 1972-07-29 1981-07-09 Basf Ag, 6700 Ludwigshafen Heterocyclische Farbstoffe, ihre Herstellung und ihre Verwendung
US5441955A (en) * 1993-11-19 1995-08-15 Pathogenesis Corporation Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues

Also Published As

Publication number Publication date
CA2415683A1 (en) 2002-01-24
DE60102473T2 (de) 2005-02-03
TR200401026T4 (tr) 2004-07-21
WO2002006284A1 (en) 2002-01-24
AR031379A1 (es) 2003-09-24
ES2218439T3 (es) 2004-11-16
CA2415683C (en) 2009-12-29
DE60102473D1 (de) 2004-04-29
JP3939246B2 (ja) 2007-07-04
EP1303517B1 (en) 2004-03-24
US6964960B2 (en) 2005-11-15
GB0017508D0 (en) 2000-08-30
MY133969A (en) 2007-11-30
US20030199502A1 (en) 2003-10-23
AU2001279754A1 (en) 2002-01-30
ATE262530T1 (de) 2004-04-15
DK1303517T3 (da) 2004-06-21
CN1441803A (zh) 2003-09-10
BR0112521A (pt) 2003-07-01
JP2004504323A (ja) 2004-02-12
PE20020210A1 (es) 2002-04-04
PT1303517E (pt) 2004-07-30
EP1303517A1 (en) 2003-04-23
HK1056872A1 (en) 2004-03-05
HK1055426A1 (en) 2004-01-09

Similar Documents

Publication Publication Date Title
CN1183136C (zh) 吲哚并喹唑啉酮
EP2197442B1 (en) Polo-like kinase inhibitors
CN110546151B (zh) 凋亡诱导剂
JP2798095B2 (ja) 特定アミノメチルフェニルイミダゾール誘導体、新種のドーパミン受容体サブタイプの特定リガンド
JP2983296B2 (ja) 新規なｎ−アミノアルキルフルオレンカルボキサミド；新規な種類のドーパミンリセプタ亜型特異性リガンド
CN110177788A (zh) 作为bcl-2选择性凋亡诱导剂的化合物
AU2001262257A1 (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
JP2002525371A (ja) Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
CN1639164A (zh) 含氮杂环化合物
JPH11504947A (ja) ドーパミンリセプタサブタイプ特異性リガンドとしてのｎ―アミノアルキルジベンゾフランカルボキサミド
CN1269811C (zh) 具有sst1拮抗活性的哌嗪衍生物
JPH11508280A (ja) 三環式アミノアルキルカルボキサミド；新規なドーパミンｄ▲下３▼受容体サブタイプに特異的なリガンド
AU7328096A (en) 2,7-substituted octahydro-pyrrolo{1,2-a}pyrazine derivatives
CN1525969A (zh) 用于治疗青光眼和近视的苯并[g]喹啉衍生物
CN1304929A (zh) 4－羟基－4－苯基哌啶衍生物及含此衍生物的药物
CN1014992B (zh) 喹唑啉二酮和吡啶并嘧啶二酮的制备方法
JP3041834B2 (ja) Ｎ―アミノアルキル―２―アントラキノンカルボキサミド；ドーパミンレセプターサブタイプに特異的な新しい配位子
EP1966167B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
HK1055426B (en) Indoloquinazolinones
JPH08269008A (ja) ディスタマイシン類似構造をもつ化合物と、それを含む抗癌剤
HK1056872B (en) Indoloquinazolinones
JP3233276B2 (ja) カッパアゴニストとしてのヒドラジド化合物
US20240239791A1 (en) Processes for the synthesis of valbenazine
CN1295070A (zh) 用于制备1型钠－氢交换剂抑制剂的方法
CN117229257A (zh) 间氨磺酰苯甲酰胺类化合物及制法、药物组合物和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1055426

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050105

Termination date: 20110716